A New Blood Cancer Approval: What Beqalzi May Mean for Mantle Cell Lymphoma Patients
A new treatment option is now approved for some people living with mantle cell lymphoma, also called MCL.
On May 13, 2026, the U.S. Food and Drug Administration granted accelerated approval to sonrotoclax, sold under the brand name Beqalzi, for adults with relapsed or refractory mantle cell lymphoma. This approval is for people who have already had at least two lines of systemic therapy, including a type of medicine called a BTK inhibitor.
That may sound like a lot of medical words. Let’s break it down.
What is mantle cell lymphoma?
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma. Lymphoma is a cancer that starts in cells of the immune system called lymphocytes. Mantle cell lymphoma affects a type of white blood cell called a B cell.
MCL is often considered an aggressive cancer, which means it can grow and spread quickly. Some people respond well to treatment at first, but the cancer can come back later. When cancer comes back after treatment, it is called relapsed. When cancer does not respond well to treatment, it is called refractory.
What is Beqalzi?
Beqalzi is the brand name for sonrotoclax. It is a targeted cancer medicine known as a BCL-2 inhibitor. BCL-2 is a protein that can help cancer cells survive. By blocking this protein, the medicine is designed to help cancer cells die.
According to the FDA, Beqalzi is approved for adults with relapsed or refractory MCL after at least two prior lines of treatment, including a BTK inhibitor.
BTK inhibitors are another type of targeted therapy used in some blood cancers. Examples of cancer treatments in this broader treatment area include medicines such as Brukinsa, Jaypirca, and other therapies used for mantle cell lymphoma.
What does “accelerated approval” mean?
Accelerated approval is a special FDA pathway. It allows certain medicines to become available sooner when they treat serious conditions and early study results suggest they may help patients.
This does not mean the treatment is a cure. It also does not mean every patient will benefit. In many cases, the company must continue studying the medicine to confirm its benefit.
For Beqalzi, the approval was based on early-to-mid-stage study results. Reuters reported that the drug showed a complete response rate of 16% in the study used for approval. A complete response means that no detectable signs of cancer were found after treatment, though this does not always mean the cancer is permanently gone.
Why this approval matters
Mantle cell lymphoma can be difficult to treat, especially after it has come back or stopped responding to earlier treatments. Patients who have already received several treatments may have fewer options.
This approval gives some patients another possible treatment to discuss with their oncology team. It is also notable because Beqalzi is the first BCL-2 inhibitor approved specifically for mantle cell lymphoma, according to Reuters.
For patients and caregivers, the key message is this: new treatment options are being developed, but the right choice depends on the person’s full medical history.
Who might be eligible?
Based on the FDA approval, Beqalzi is for:
Adults with relapsed or refractory mantle cell lymphoma who have already received at least two prior lines of systemic therapy, including a BTK inhibitor.
This means it is not necessarily for every person with mantle cell lymphoma. It may not be used as the first treatment after diagnosis. Eligibility depends on prior treatments, current health, lab results, side effects, and the judgment of the oncology team.
Questions to ask your cancer care team
If you or a loved one has mantle cell lymphoma, consider asking:
Am I eligible for Beqalzi based on my past treatments?
What are the possible benefits in my situation?
What side effects should I watch for?
How often would I need blood tests or follow-up visits?
How does this compare with other options, such as CAR-T therapy, BTK inhibitors, clinical trials, or other medicines?
Is this treatment available now, and will insurance cover it?
These questions can help you and your care team make a decision together.
A note for caregivers
Caregivers often help track appointments, symptoms, medications, and questions. With a new treatment, it can be helpful to keep a notebook or phone note with:
Medication names and doses
Side effects or new symptoms
Questions for the next visit
Insurance or pharmacy updates
Emergency contact instructions from the care team
Cancer treatment can feel overwhelming. You do not have to remember everything at once. Ask the care team to explain the plan in plain language and repeat anything that is unclear.
The bottom line
Beqalzi is a new FDA-approved treatment option for certain adults with relapsed or refractory mantle cell lymphoma. It works by targeting BCL-2, a protein that helps some cancer cells survive.
This is encouraging news, especially for patients who have already tried multiple treatments. But it is important to remember that accelerated approval is based on early evidence, and more research is usually needed to confirm long-term benefit.
If mantle cell lymphoma has returned or stopped responding to treatment, ask your oncology team whether Beqalzi or another treatment option may be right for you.
Reference
“FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma.”
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making any changes to your treatment plan, hydration strategies, or diet. The information provided here is based on general insights and may not apply to individual circumstances.
